|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 尿激酶治疗急性心肌梗塞多中心临床试验1406例总结显示文摘为观察尿激酶天普洛欣(UKTP)经静脉溶栓治疗急性心肌梗塞(AMI)的临床有效性及安全性。收集协作组148家医院1994年11月至1996年4月经静脉UKTP溶栓治疗AMI患者1406例,观察临床疗效、副作用及病死率等。其中124例行90分钟冠状动脉造影评价梗塞血管开通情况。结果:梗塞血管临床再灌注率为73.5%,90分钟冠状动脉造影血管开通率为72.6%,5周总病死率为7.8%(109/1406),轻度出血10.2%(143/1406),中重度出血0.43%(6/1406),脑出血0.50%(7/1406)。老年(>65岁)甚至高龄(>75岁)患者溶栓及距发病超过6小时者,其用药仍然安全有效,UKTP合适的用药剂量可能为150万U左右。结果提示UKTP治疗AMI安全有效。 | The collaborative study group for national multicenter clinical trial of urokinase thrombolytic therapy (Correspondence: Hu Dayi, Xu Zhimin. Beijing Red Cross Chao Yao Hospital, Beijing 100020) | 1997 | 中华心血管病杂志1997，25，3： | 139 |
| 2 | 重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验显示文摘目的研究新型溶栓剂——重组葡激酶(r-Sak)治疗急性心肌梗死(AMI)的冠状动脉通畅率、临床疗效及安全性。方法本研究为多中心、随机、平行对照临床试验,入选发病12 h 内、年龄≤70岁、ST 段抬高的 AMI 患者,随机分为 r-Sak 组104例,给予 r-Sak 3 mg 静注,12 mg 于30 min 内静脉输注,总量15 mg;重组组织型纤溶酶原激活剂(rt-PA)组106例,8 mg 静注,42 mg 在90 min 内输注,总量50 mg。全部患者给予阿司匹林和静脉输注肝素,于用药90 min 行冠状动脉造影,对 TIMI 血流0~2级者行补救性 PCI。结果主要终点:用药90 min 冠状动脉通畅率(TIMI 血流2级或3级),r-Sak 组明显高于 rt-PA 组(77.8%比63.6%,P=0.0277),TIMI 3级者两组间差异无统计学意义(57.6%比48.5%,P=0.1929);1个月内死亡(8.7%比5.7%,P=0.3997)、非致死性再梗死(2.9%比3.8%,P=1.0000)、心肌缺血复发(8.7%比16.0%,P=0.1043)和复合临床终点(18.3%比21.7%,P=0.5345)两组间差异均无统计学意义。次要终点:r-Sak 组出血发生率(28.8%)与 rt-PA组(27.4%)比较,差异无统计学意义(P=0.8105),其中严重或威胁生命的出血,两组间差异亦无统计学意义(1.9%比3.8%),r-Sak 组脑出血1例(0.96%),rt-PA 组脑出血4例(3.85%)。无其他药物相关的严重不良反应及过敏反应发生。结论 r-Sak 是一种安全、有效的治疗 AMI 的溶栓药物,其疗效及安全性至少与 rt-PA 50 mg 相似。 | Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction | 2007 | 中华心血管病杂志2007，35，8： | 43 |
| 3 | 慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新显示文摘抗病毒治疗是慢性乙型肝炎(CHB)治疗的关键。近年来随着抗病毒治疗不断进展,一般患者的治疗逐渐趋于规范,而CHB特殊患者由于循证医学证据相对不足、相关指南无统一的推荐意见等原因成为临床治疗的难点。为进一步规范这些特殊患者的治疗,2010年《中华实验和临床感染病杂志(电子版)》、《临床肝胆病杂志》与《中国肝脏病杂志(电子版)》编辑部组织相关专家对相关资料进行整理与分析, | Expert Committee for Antiviral Therapy for Special Patients with Chronic Hepatitis B | 2015 | 临床肝胆病杂志2015，31，8： | 32 |
| 4 | Mechanism of exosomal microRNA-224 in development of hepatocellular carcinoma and its diagnostic and prognostic value显示文摘BACKGROUND Exosomes contain proteins, lipids, and biological molecules such as DNA and RNA. Nucleic acids in exosomes are a group of molecules that can act as biomarkers. Currently, there are many reports on exosomal microRNAs, which are ideal biomarkers for the early diagnosis of cancer. However, there are few reports on the role of exosomal microRNAs in the diagnosis and prognosis of hepatocellular carcinoma(HCC).AIM To understand the mechanism of exosomal microRNA-224(miR-224) in the development of HCC and evaluate its diagnostic and prognostic value.METHODS Cell culture and transfection of exosomal miRNA-224, real-time quantitative PCR, luciferase reporter assay, and other methods were used to find new biomarkers related to the development of HCC that can be used to diagnose HCC and predict HCC prognosis.RESULTSBy targeting glycine N-methyltransferase, incubating exosomes with miR-224 mimic resulted in a significant increase in cell proliferation compared to that of the control group, while incubation with the miR-224 inhibitor significantly reduced cell proliferation. The same results were obtained for the cell invasion assay. Serum exosomal miR-224 did have some ability to differentiate patients with HCC from healthy controls, with an area under the curve of 0.910, and HCC patients with higher serum exosomal miR-224 expression had lower overall survival.CONCLUSION Exosomal miR-224 is a tumor promotor and can be a marker of diagnosis and prognosis of HCC patients, however, its ability to distinguish liver diseases needs further verification. | Yao Cui Hai-Feng Xu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Interventional Therapy Department Peking University Cancer Hospital and Institute Ming-Yue Liu Yu-Jie Xu Jun-Chuang He Yun Zhou Shun-Dong Cang | 2019 | World Journal of Gastroenterology2019，25，15： | 26 |
| 5 | Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients显示文摘BACKGROUND: The outcome of surgical treatment of pa- tients with intrahepatic cholangiocarcinoma (ICC) is poor. This study was designed to analyze the relationship between clinicopathologic features and the survival time after opera- tion. METHODS: The operation was performed in 104 patients with mass-forming type ICC at our hospital between No- vember 1996 and May 2000. Seventy-nine patients (76.0%) were followed up successfully. Sixteen clinicopathological variables including age, sex, history of chronic liver di- sease , HBsAg, operation, adjuvant therapy, ascites, lymph node metastasis, invasion of adjacent organs, tumor size, necrosis of tumor, envelope, intrahepatic metastasis, Inter- national Union Against Cancer (UICC) TNM staging, his- tology, and cirrhosis were selected for univariate and multi- variate analyses to evaluate their influence on the prognosis. RESULTS: The accumulative 1-, 3-, 5-year survival rates of the 79 patients were 49.4%, 17.3%, 9.6% respectively. Univariate analysis revealed that sex (P=0.0221), HBsAg (P=0.0115), operation (P=0.0042), adjuvant therapy (P= 0.0389), ascites (P=0.0001), invasion (P=0.0220), intra- hepatic metastasis (P=0.0000) and TNM stage (P= 0.0001) were related to survival time. Multivariate analysis revealed that HBsAg, ascites and TNM stage were signifi- cantly related to prognosis. CONCLUSION: Early diagnosis and treatment and major hepatectomy are essential to improving the results of surgi- cal treatment of ICC patients. | Xiao-Hui Fu, Zhao-Hui Tang, Ming Zong, Guang-Shun Yang, Xiao-Ping Yao and Meng-Chao Wu Shanghai, China Department of Comprehensive Therapy of Hepatobi- liary Tumors, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，2： | 24 |
| 6 | Preparation of human single chain Fv antibody against hepatitis C virus E2 protein and its identification in immunohistochemistry显示文摘AIM: To screen human single chain Fv antibody (scFv)against hepatitis C virus E2 antigen and identify its applicationin immunohistochemistry.METHODS: The phage antibody library was panned by HCVE2 antigen, which was coated in microtiter plate. After fiverounds of biopanning,56 phage clones were identified specificto HCV E2 antigen. The selected scFv clones were digestedby SfiI/NotI and DNA was sequenced. Then it was subclonedinto the vector pCANTABSE for expression as E-taggedsoluble scFv. The liver tissue sections from normal personand patients with chronic hepatitis B and chronic hepatitis Cwere immunostained with HCV E2 scFv antibody.RESULTS: The data of scFv-E2 DNA digestion and DNAsequencing showed that the scFv gene is composed of 750bp. ELISA and immunohistochemistry demonstrated that thehuman single chain Fy antibody against hepatitis C E2 antigenhas a specific binding character with hepatitis virus E2 antigenand paraffin-embedded tissue, but did not react with liver tissuesfrom healthy persons or patients with chronic hepatitis B.CONCLUSION: We have successfully screened andidentified HCV E2 scFv and the scFv could be used in theimmunostaining of liver tissue sections from patients withchronic hepatitis C. | Yan-Wei Zhong Jun Cheng Gang Wang Shuang-Shuang Shi Li Li Ling-Xia Zhang Ju-Mei Chen Gene Therapy Research Center,Institute of Infectious Diseases,302 Hospital of PLA,26 Fengtai Road,Beijing 100039,China | 2002 | World Journal of Gastroenterology2002，8，5： | 21 |
| 7 | 水飞蓟制剂肝病临床应用专家共识显示文摘随着水飞蓟制剂循证医学证据的积累,水飞蓟制剂已被多部肝病诊疗指南列为抗炎保肝治疗药物。但限于篇幅,上述指南均未就水飞蓟制剂的具体临床应用展开论述,也未能给出详尽的循证医学证据。为此,我们根据临床水飞蓟制剂在各种肝病临床应用的结果作为循证医学的证据,参照肝病治疗、诊疗各项指南和共识,结合肝病治疗的发展趋势,讨论并撰写本专家共识,以期为临床医生进一步提供更为可靠的用药依据。 | Committee of experts on silymarin therapy in patients with liver diseases | 2016 | 中华实验和临床感染病杂志(电子版)2016，10，5： | 16 |
| 8 | Plasmacytoid Dendritic Cells Act as the Most Competent Cell Type in Linking Antiviral Innate and Adaptive Immune Responses显示文摘Appropriate in vivo control of plasmacytoid dendritic cell (pDC) recruitment and activation is a fundamental requirement for defense against viral infection. During this process, a pivotal event that influences the outcome of viral infection is the production of high levels of type I interferon by pDCs. In particular, recent research findings showed that pDCs not only shape the nature of innate resistance, but are also responsible for the successful transition from innate to adaptive immunity for viral resistance. In addition, pDCs can differentiate into antigen presenting cells that may regulate tolerance to a given pathogen. Importantly, in a series of recent clinical studies,pDCs appeared to be defective in number and function in conditions of chronic viral diseases such as infected with HIV-1, HBV or HCV. pDC-associated clinical antiviral therapy is also emerging. This review describes research findings exanining the functional and antiviral properties of in vivo pDC plasticity. | Zheng Zhang~1 Fu-Sheng Wang~(1,2) ~1Research Center of Biological Therapy,Beijing 302 Hospital,Beijing 100039,China ~2Research Centre of Biological Therapy,Beijing Institute of Infectious Diseases,Beijing 302 Hospital,100 Xi Si Huan Middle Road,Beijing 100039,China. | 2005 | Cellular & Molecular Immunology2005，2，6： | 16 |
| 9 | Copper-chelating therapeutic effect in Wilson disease with different clinical phenotypes and polymorphisms of ATP7B gene显示文摘CopperchelatingtherapeuticefectinWilsondiseasewithdiferentclinicalphenotypesandpolymorphismsofATP7BgeneRENMingShan1,HUWen?.. | REN MingShan1, HU WenBin1, ZHANG Zhi1, JU ShuangWu1, FAN YuXin2, WANG GongQiang1 and YANG RenMin1Keywords Wilson disease/therapy copper chelating agents ATP7B gene mutations | 1998 | World Journal of Gastroenterology1998，4，4： | 15 |
| 10 | Detection of soluble TRAIL in HBV infected patients and its clinical implications显示文摘AIM: To detect the expression of soluble TRAIL (TNF-related apoptosis inducing ligand, TRAIL) in the peripheral blood of HBV infected patients and try to elucidate whether the expression level of sTRAIL have any correlativity with the clinical staging, the expression level of HBV markers and the degree of liver damage.METHODS: 52 cases of HBV infected patients were investigated, induding 8 HBV carriers, 30 chronic hepatitis B, 11 drrhotics and 3 HBV infection related hepatocellular carcinoma. Expression of soluble TRAIL and markers of the hepatitis B were mearsured by enzyme-linked immunosorbent assay.RESULTS: The expression level of sTRAIL in the peripheral blood of the HBV infected patients was significantly higher than that of healthy controls (1378.35±540.23 pg/ml vs 613.75±175.80 pg/ml, P<0.001). In the group of chronic hepatitis, the expression level of sTRAIL was coincident with the status of the disease and was significantly correlated with the level of ALT. In the group of cirrhosis and liver cancer, its expression level was significantly higher than that of the healthy persons and HBV carriers, but lower than that of the hepatitis B patients; meanwhile, the expression of siRAIL did not have any correlativity with the functional indexes of the liver. CONCLUSION: The soluble TRAIL in the HBV infected people may participate in the liver damage. Our results indicated that the expression level of soluble TRAIL may reflect the ravage of liver caused by host immune reaction to a certain degree. | Li-Hui Han Wen-Sheng Sun Chun-Hong Ma Li-Ning Zhang Su-Xia Liu Qiu Zhang Li-Fen Gao,Institute of Immunology,Medical College of Shandong University,Jinan 250012,Shandong Province,China You-Hai Chen,Institute for Human Gene Therapy,University of Pennsylvania,Philadelphia PA 19104,USA | 2002 | World Journal of Gastroenterology2002，8，6： | 12 |
| 11 | 90分钟冠状动脉造影评价急性心肌梗塞血管开通及临床再通指标价值显示文摘通过经静脉溶栓开始后90分钟冠状动脉造影(CAG),观察国产尿激酶(天普洛欣,UKTP)静脉溶栓治疗急性心肌梗塞(AMI)血管开通疗效,并评价临床再灌注标准的判断价值如何。方法:从UKTP多中心治疗AMI1406例中,汇集其中所行冠状动脉造影(CAG)共124例资料。结果提示:(1)124例AMI患者,在溶栓开始后90分钟时的梗塞相关血管的血流达TIMIⅢ级者52例(41.9%)、Ⅱ级38例(30.7%),梗塞相关血管再开通率为72.6%;(2)溶栓距起病时间愈早,具有愈高的开通趋势,但差异无统计学意义;(3)以CAG为金标准,临床标准对血管开通判断敏感性为88%,特异性为69%,准确性为83%。结论:UKTP静脉溶栓治疗AMI血管开通疗效肯定,临床标准判断血管再通的敏感性较高,但特异性欠佳,有待提高。 | The multicentre investigating group of thrombolytic therapy on acute myocardial infarction with Urokinase Techpool Correspondence: Hu Dayi, Xu Zhimin. Chaoyang Red Cross Hospital, Capital University of Medical Sciences, Beijing 100020 | 1997 | 中华心血管病杂志1997，25，4： | 11 |
| 12 | Single-nucleotide polymorphisms among microRNA:big effects on cancer显示文摘MicroRNAs(miRNAs) are small non-coding RNAs that regulate gene expression at the transcriptional or posttranscriptional level.Many miRNAs are found to play a significant role in cancer development either as tumor suppressor genes or as oncogenes.Examination of tumor-specific miRNA expression profiles in diverse cancers has revealed widespread deregulation of these molecules,whose loss and overexpression respectively have diagnostic and prognostic significance.Genetic variations,mostly single-nucleotide polymorphisms(SNPs) within miRNA sequences or their target sites,have been found to be associated with many kinds of cancers.In this review,we summarize the current knowledge of miRNAs including their biogenesis and role in cancer development,and finally,how SNPs among miRNAs affect miRNA biogenesis and contribute to cancer. | Feng-Ju Song1,2 and Ke-Xin Chen1,2 Department of Epidemiology and Biostatistics,1Tianjin Medical University Cancer Hospital and Institute,Tianjin 300060,P.R.China Key Laboratory of Breast Cancer Prevention and Therapy,2Tianjin Medical University,Ministry of Education,Tianjin 300060,P.R.China | 2011 | Chinese Journal of Cancer2011，30，6： | 11 |
| 13 | Traditional Chinese medicine “Qing Yi Tang” alleviates oxygen free radical injury in acute necrotizing pancreatitis显示文摘TraditionalChinesemedicine“QingYiTang”aleviatesoxygenfreeradicalinjuryinacutenecrotizingpancreatitisLIZhanLiang1,WUChengTan... | LI ZhanLiang1, WU ChengTang2, LU LianRong, ZHU XiaoFeng and XIONG DeXinKeywords pancreatitis/therapy Qing Yi Tang free radicals superoxide dismutase/analysis malonyldiadehyde/analysis | 1998 | World Journal of Gastroenterology1998，4，4： | 8 |
| 14 | 慢性乙型肝炎核苷(酸)类似物经治患者抗病毒治疗专家共识:2016年更新显示文摘多数慢性乙型肝炎患者经过核苷(酸)类似物抗病毒治疗后,远期预后可获得显著改善,但仍有部分患者在治疗后发生原发无应答、应答不佳以及复发。为规范慢性乙型肝炎经治患者的再治疗,2013年我们组织国内部分专家讨论并形成了《慢性乙型肝炎核苷(酸)类似物经治患者抗病毒治疗专家共识》。近3年来,符合循证医学原则的研究数据不断增加,对慢性乙型肝炎核苷(酸)类似物(NAs)经治患者抗病毒治疗的认识亦有提高。因此,我们再次组织专家对相关最新资料进行分析整理,形成本共识的2016年更新。 | Committee of experts on antiviral therapy in nucleos(t)ide analogues experienced chronic hepatitis B patients | 2016 | 中国肝脏病杂志(电子版)2016，8，3： | 8 |
| 15 | 水飞蓟制剂肝病临床应用专家共识显示文摘随着水飞蓟制剂循证医学证据的积累,水飞蓟制剂已被多部肝病诊疗指南列为抗炎保肝治疗药物。但限于篇幅,上述指南均未就水飞蓟制剂的具体临床应用展开论述,也未能给出详尽的循证医学证据。为此,我们根据临床水飞蓟制剂在各种肝病临床应用的结果作为循证医学的证据,参照肝病治疗诊疗各项指南和共识,结合肝病治疗发展趋势,讨论并撰写本专家共识,以期为临床医生进一步提供更为可靠的用药依据。 | Committee of experts on silymarin therapy in patients with liver diseases | 2016 | 中国肝脏病杂志(电子版)2016，8，3： | 6 |
| 16 | Expression,purification and immunocharacteristics of recombination UreB protein of H.pylori显示文摘INTRODUCTIONHelicobacter pylori (H . pylori) is associated with the development of chronic gastritis ,peptic ulcer and gastric cancer and gastric MALT lymphoma[1-9],H .pylori has many antigens ,including urease ,heat shock protein and vacuolating cytotoxin and so on ,and urease is an important factor in the colinization of the gastric mucosa and suspected to cause damage to the gastric mucosa[10-14].At the same time ,urdase is also one of the important protective antigens . | Chao Wu~1 Quan Ming Zou~1 Hong Guo~2 Xiao Peng Yuan~1 Wei Jun Zhang~1 Dong Shui Lu~1 Xu Hu Mao~1 ~1Department of Clinical Microbiology,Third Military Medical University,Chongqing 400038,China ~2Department of Gastroenterology,Xinqiao Hospital,Third Military Medical University,Chongqing 40003?,ChinaDr.Chao Wu graduated from Third Military Medical University as a postgraduate in 2000,now a lecturer,specialized in diagnosis,prevention and therapy of Helicobacter pylori infection,having 6 papers published. | 2001 | World Journal of Gastroenterology2001，7，3： | 5 |
| 17 | Effects of glucocorticoid and cysteinyl leukotriene 1 receptor antagonist on CD_(34)^+ hematopoietic cells in bone marrow of asthmatic mice显示文摘Background Corticosteroids remain the most effective therapy available for asthma. They have widespread effects on asthmatic airway inflammation. However, little is known about the effects of corticosteroids on the production of bone marrow inflammatory cells in asthma. This study observed the effects of glucocorticoid and cysteinyl leukotriene 1 receptor antagonist on CD 34 + hematopoietic cells, so as to explore the possible effectiveness of a bone marrow-targeted anti-inflammatory strategy. Methods Balb/c mice were sensitized and challenged with ovalbumin (OVA) to establish an asthmatic model. For two consecutive weeks, asthmatic mice were challenged with OVA while being given either prednisone, montelukast, prednisone plus montelukast, or sterile saline solution. The mice were killed 24 hours after the last challenge with OVA, and bronchoalveolar lavage fluid (BALF), peripheral blood, and bone marrow were collected. Eosinophils in peripheral blood and BALF, and nucleated cells in BALF, peripheral blood, and bone marrow were counted. The percentages of CD 34 + cells, CD 4 + T lymphocytes and CD 8 + T lymphocytes among nucleated cells in peripheral blood and bone marrow were counted by flow cytometry. Immunocytochemistry and in situ hybridization were employed to detect expression of CD 34 and interleukin (IL)-5Rα mRNA (CD 34 + IL-5Rα mRNA + cells) among bone marrow hematopoietic cells. Results Compared with the sterile saline solution group, the number of eosinophils in BALF and peripheral blood, CD 34 + cells in peripheral blood and bone marrow, and CD 34 + IL-5Rα mRNA + cells in bone marrow of mice from the prednisone and prednisone plus montelukast groups were significantly lower (P<0.01). The number of eosinophils in BALF from the montelukast group was also significantly lower (P<0.05). Conclusions The results suggest that, in this asthmatic mouse model, prednisone probably inhibits proliferation, differentiation, and migration of CD 34 + cells in bone marrow, blocks eosinophilopoiesis in bone marrow, and interferes with eosinophil migration into peripheral blood and subsequent recruitment in the airway. In addition, montelukast may suppress eosinophil infiltration into the lungs of asthmatic mice. However, a significant inhibitory effect of montelukast on the proliferation and migration of CD 34 + cells and a cooperating effect with prednisone on bone marrow of asthmatic mice were not observed. | 毛辉 殷凯生 王曾礼 李富宇Department of General Surgery West China Hospital 张希龙 刘春涛 雷松Department of Tumor Biological Therapy West China Hospital | 2004 | Chinese Medical Journal2004，，4： | 5 |
| 18 | Cells therapy for Parkinson's disease-so close and so far away显示文摘One of the strategies of treating Parkinson's disease(PD) is the replacement of lost neurons in the substantia nigra with healthy dapamingergic cells.Potential sources for cells range from autologous grafts of dopamine secreting cells,fetal ventral mesencephalon tissue,to various stem cell types.Over the past quarter century,many experimental replacement therapies have been tried on PD animal models as well as human patients,yet none resulted in satisfactory outcomes that warrant wide applications.Recent progress in stem cell biology has shown that nuclear transfer embryonic stem cells(ntES) or induced pluripotent stem cells(iPS) derived cells can be used to successfully treat rodent PD models,thus solving the problem of immunorejection and paving the way for future autologous transplantations for treating PD.Meanwhile,however,post mortem analysis of patients who received fetal brain cell transplantation revealed that implanted cells are prone to degeneration just like endogenous neurons in the same pathological area,indicating long-term efficacy of cell therapy of PD needs to overcome the degenerating environment in the brain.A better understanding of neurodegeneration in the midbrain appeared to be a necessary step in developing new cell therapies in Parkinson's disease.It is likely that future cell replacement will focus on not only ameliorating symptoms of the disease but also trying to slow the progression of the disease by either neuroprotection or restoring the micro-environment in the midbrain. | REN ZhenHua & ZHANG Yu Cell Therapy Center,Xuanwu Hospital,Capital Medical University and Key Laboratory of Neurodegeneration,Ministry of Education,Beijing 100053,China | 2009 | Science China(Life Sciences)2009，52，7： | 4 |
| 19 | Therapeutic effect of transcatheter arterial chemoembolization and percutaneous injection of acetic acids on primary liver cancer显示文摘BACKGROUND: The resection rate of primary liver tumor in China is only about 20%. A lot of patients with moderate and advanced liver tumor may lose the chance of opera- tion. The objective of present research was to study the ef- ficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous injection of chemical agents and acetic acids in the treatment of patients with primary liver cancer (PLC). METHODS: Thirty-three patients with middle and ad- vanced stage of PLC were divided into two groups: percu- taneous injection of chemical agents and acetic acids (15 patients, group A) and TACE (18 patients, group B). RESULTS: Tumor diameter and serum AFP level reduced to 86.6% and 83.3% in group A, and 55.5% and 40% in group B, respectively. There was significant difference be- tween the two groups ( P < 0 . 0 1 ) . The 1-, 2-, 3-, 4-year survival rates of group A were 96.7%, 86.6%, 51.3%, 33.3%, respectively and in group B were 66.7%, 44.4%, 16.7%, 0%, respectively (P<0.01). CONCLUSION: TACE combined with percutaneous injec- tion of chemical agents and acetic acids is efficacious to in- crease the survival rate of patients with PLC. | Hong-Bin Chen, Yue Huang, Dong-Ling Dai, Xia Zhang, Zhong-Wen Huang, Qi-Kai Zhang, Hui-Hua Wang, Jun-Su Zhang and Ge Pan Sanming, China Departments of Gastroenterology , Interventional Therapy , Ultrasonography and CT , Sanming Municipal First Hospital, Sanming 365000, China Department of Gastroenterology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400000, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，1： | 4 |
| 20 | Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells显示文摘Objective:We aimed to perform a preliminary study of the association between induced pluripotent stem cell(iPS)-related genes and biological behavior of human colorectal cancer(CRC) cells,and the potential for developing anti-cancer drugs targeting these genes.Methods:We used real-time reverse transcriptase polymerase chain reaction(RT-PCR) to evaluate the transcript levels of iPS-related genes NANOG,OCT4,SOX2,C-MYC and KLF4 in CRC cell lines and cancer stem cells(CSCs)-enriched tumor spheres.NANOG was knockdowned in CRC cell line SW620 by lentiviral transduction.3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assays,plate colony formation,and a mouse xenograft model were used to evaluate alterations in biological behavior in NANOG-knockdown SW620 cells.Also,mock-knockdown and NANOG-knockdown cells were treated with 5-fluorouracil(5-FU) and survival rate was measured by MTT assay to evaluate drug sensitivity.Results:A significant difference in the transcript levels of iPS-related genes between tumor spheres and their parental bulky cells was observed.NANOG knockdown suppressed proliferation,colony formation,and in vivo tumorigenicity but increased the sensitivity to 5-FU of SW620 cells.5-FU treatment greatly inhibited the expression of the major stemness-associated genes NANOG,OCT4,and SOX2.Conclusions:These results collectively suggest an overlap between iPS-related genes and CSCs in CRC.Quenching a certain gene NANOG may truncate the aggressiveness of CRC cells. | Zhong SHI1,Rui BAI1,Zhi-xuan FU1,Yong-liang ZHU2,Rong-fu WANG3,Shu ZHENG1(1Cancer Institute(Key Laboratory of Cancer Prevention and Intervention,China National Ministry of Education,Key Laboratory of Molecular Biology in Medical Sciences,Zhejiang Province,China),the Second Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310009,China)(2Department of Gastroenterology,the Second Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310009,China)(3Center for Cell and Gene Therapy,Department of Pathology and Immunology,Baylor College of Medicine,Houston,Texas 77030,USA) | 2012 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2012，13，1： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员